within Pharmacolibrary.Drugs.C_CardiovascularSystem.C07A_BetaBlockingAgents.C07AG01_Labetalol;
model Labetalol 
   extends Pharmacolibrary.Drugs.ATC.C.C07AG01;

  annotation(Documentation(
    info ="<html><body><p>Labetalol is a combined alpha- and beta-adrenergic receptor antagonist used primarily for the treatment of hypertension, including hypertensive emergencies and chronic hypertension. It is approved for clinical use and is widely prescribed today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from healthy adult volunteers after a single intravenous dose.</p><h4>References</h4><ol><li><p>MacCarthy, EP, &amp; Bloomfield, SS (1983). Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. <i>Pharmacotherapy</i> 3(4) 193–219. DOI:<a href=&quot;https://doi.org/10.1002/j.1875-9114.1983.tb03252.x&quot;>10.1002/j.1875-9114.1983.tb03252.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6310529/&quot;>https://pubmed.ncbi.nlm.nih.gov/6310529</a></p></li><li><p>Carter, BL (1983). Labetalol. <i>Drug intelligence &amp; clinical pharmacy</i> 17(10) 704–712. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6354658/&quot;>https://pubmed.ncbi.nlm.nih.gov/6354658</a></p></li><li><p>Daneshmend, TK, &amp; Roberts, CJ (1982). The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. <i>British journal of clinical pharmacology</i> 14(1) 73–78. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1982.tb04936.x&quot;>10.1111/j.1365-2125.1982.tb04936.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7104169/&quot;>https://pubmed.ncbi.nlm.nih.gov/7104169</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Labetalol;
